

*Supplementary Materials*

# Physicochemical, Pharmacokinetic and Cytotoxicity of the Compounds Isolated from an Endophyte *Fusarium oxysporum*: In Vitro and In Silico Approaches

## 1. The Plant *Aglaonema hookerianum* Schott.


In this study, a fungal endophyte *Fusarium oxysporum*, isolated from petiole of *Aglaonema hookerianum* Schott (Family: Araceae) growing in the forest of Sylhet and Chittagong Hill tracks of Bangladesh has been investigated. It is a herb, stem erect, 40–50 cm or more tall, 1.5–2.0 cm thick, internodes 1.5–3.0 cm long. Leaves petiolate, petiole up to 24 cm long and grows in the shady areas of deep forest. A large number of tribal populations like Chakma, Marma, Murong, Tongchongya, Tripura, Chak, Khasia, Rheyang, Rakhain, Khumi etc live as forest inhabitants in the remote areas throughout Sylhet and the Chittagong Hill Tracts, where there is no or poor modern medical systems of health care. The majority of them are dependent on the traditional system of treatment, which includes various indigenous medicinal plants of those areas [1]. *A. hookerianum*, locally known as Habinishak, is used by the mainstream traditional practitioners of Sylhet district for the treatment of hemorrhoids and arthritis. One tablespoon decoction prepared from the roots of *A. hookerianum* is taken orally twice daily for the treatment of gout. The sap from the root is taken for conjunctivitis and constipation by Chakma community. The leaf extract, applied to the whole body, is used for the treatment of hysteria by Tanchangya community [2]. The petiole of *A. hookerianum* is used in the preparation of 'Shuktani', which is an ethno-medico recipe used in the treatment of stomach disorders like diarrhea, indigestion and dysentery by the Sylheti Bengali Community of Barak Valley, Southern Assam, India [3]. Previous phytochemical study revealed the presence of alkaloid, glycoside, tannin, reducing sugar, saponin and gum in the ethanolic extract of *A. hookerianum*. The extract of this plant also showed potent antibacterial and cytotoxic activities [4].




**Figure S1.** Herbarium sheets of *Aglaonema hookerianum* plant deposited in Bangladesh National Herbarium (BNH).



**A**




**B**






**Figure S2.** Microscopical characters of *Fusarium oxysporum* **A-B:** Macroconidia and microconidia; **C-D:** Measurements of macroconidia and microconidia.

## 2. NMR and Mass Spectra of Compounds 1–5




**Figure S3.** <sup>1</sup>H nuclear magnetic resonance (NMR) spectrum (400 MHz,  $\text{CDCl}_3$ ) of compound 1.


Figure S4.  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CDCl}_3$ ) of compound 1.Figure S5.  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CDCl}_3$ ) of compound 1 (expanded).




**Figure S6.**  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CDCl}_3$ ) of compound 1 (expanded).




**Figure S7.**  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CDCl}_3$ ) of compound 1 (expanded).




**Figure S8.**  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CDCl}_3$ ) of compound 1 (expanded).




**Figure S9.**  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CDCl}_3$ ) of compound 2.




**Figure S10.** <sup>1</sup>H NMR spectrum (400 MHz, CDCl<sub>3</sub>) of compound 2 (expanded).



**Figure S11.** <sup>1</sup>H NMR spectrum (400 MHz, CDCl<sub>3</sub>) of compound 2 (expanded).




**Figure S12.**  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CDCl}_3$ ) of compound 2.




**Figure S13.**  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CDCl}_3$ ) of compound 2 (expanded)


FIGURE




**Figure S14.** Distortionless enhancement by polarization transfer (DEPT)-135 spectrum of compound 2.




**Figure S15.** High-resolution mass spectrometry (HRMS) of compound 2.




**Figure S16.**  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CDCl}_3$  with 2 drops of MeOD) of compound 3.




**Figure S17.**  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CDCl}_3$  with 2 drops of MeOD) of compound 3. (expanded).




**Figure S18.**  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CDCl}_3$  with 2 drops of MeOD) of compound 3.





**Figure S19.** DEPT-135 spectrum of compound 3.




**Figure S20.**  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CDCl}_3$ ) of compound 4.




**Figure S21.**  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CDCl}_3$ ) of compound 4 (expanded).

Figure S22.  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CDCl}_3$ ) of compound 4 (expanded).Figure S23.  $^{13}\text{C}$  NMR spectrum (100 MHz,  $\text{CDCl}_3$ ) of compound 4.



**Figure S24.** <sup>13</sup>C NMR spectrum (100 MHz, CDCl<sub>3</sub>) of compound 4 (expanded).



**Figure S25.** DEPT-135 spectrum of compound 4.




Figure S26. <sup>1</sup>H-<sup>1</sup>H Correlation spectroscopy (COSY) spectrum of compound 4.







Figure S27. Heteronuclear single quantum coherence or heteronuclear single quantum correlation experiment (HSQC) spectrum of compound 4.




**Figure S28.** Heteronuclear multiple bond correlation (HMBC) spectrum of compound 4.




**Figure S29.** HRMS spectrum of compound 4.




**Figure S30.**  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CDCl}_3$ ) of compound 5.



**Figure S31.**  $^1\text{H}$  NMR spectrum (400 MHz,  $\text{CDCl}_3$ ) of compound 5 (expanded).



**Figure S32.** <sup>1</sup>H NMR spectrum (400 MHz, CDCl<sub>3</sub>) of compound 5 (expanded).



**Figure S33.** <sup>13</sup>C NMR spectrum (100 MHz, CDCl<sub>3</sub>) of compound 5.




Figure S34. DEPT-135 spectrum of compound 5.




Figure S35. COSY spectrum of compound 5.




Figure S36. HSQC spectrum of compound 5.










Figure S37. HMBC spectrum of compound 5.




**Figure S38.** HRMS spectrum of compound 5.




**Figure S39.** X-ray crystallography of compound 5.




**Figure S40.** Effect of the compounds **1**, **3**, **4** and **5** on Vero cells compared to the control DMSO. All the compounds reduced the cell viability at the concentration of  $20.0\mu\text{M}$  except compound **1**. Here, control = DMSO, **1** =  $3\beta,5\alpha$ -dihydroxy-ergosta-7,22-diene-6-one, **3** = *p*-hydroxybenzaldehyde, **4** = 3-(*R*)-7-butyl-6,8-dihydroxy-3-pent-11-enylisochroman-1-one, **5** = Beauvericin.





**Figure S41.** Outcomes of compound 1 while running in SwissADME.



**Figure S42.** Outcomes of compound 1 while running in Cell Line Cytotoxicity Predictor (CLC-Pred) online tool.



**Figure S43.** Outcomes of compound 2 while running in SwissADME.

**Figure S44.** Outcomes of compound 3 while running in SwissADME.**Figure S45.** Outcomes of compound 3 while running in pkCSM online tool.

pkCSM  Predict Theory Help Contact Acknowledgements Related Resources License (non-academic)

**Molecule Depiction**

**SMILES**

Property	Model Name	Predicted Value	Unit
Toxicity	AMES toxicity	No	Categorical (Yes/No)
Toxicity	Max. tolerated dose (human)	-0.318	Numeric (log mg/kg/day)
Toxicity	hERG I inhibitor	No	Categorical (Yes/No)
Toxicity	hERG II inhibitor	Yes	Categorical (Yes/No)
Toxicity	Oral Rat Acute Toxicity (LD50)	2.097	Numeric (mol/kg)
Toxicity	Oral Rat Chronic Toxicity (LOAEL)	1.999	Numeric (log mg/kg_bw/day)
Toxicity	Hepatotoxicity	No	Categorical (Yes/No)
Toxicity	Skin Sensitisation	No	Categorical (Yes/No)
Toxicity	T.Pyrimiformis toxicity	1.491	Numeric (log ug/L)
Toxicity	Minnow toxicity	-0.24	Numeric (log mM)

**Molecule properties:**

Descriptor	Value
Molecular Weight	304.386
LogP	3.6782
#Rotatable Bonds	6
#Acceptors	4
#Donors	2
Surface Area	130.979

**Run another prediction** **Back**



THE UNIVERSITY OF  
MELBOURNE

UNIVERSITY OF  
CAMBRIDGE


OPEN KNOWLEDGE

Best viewed using Chrome on 1280x1024 resolution and above

Figure S46. Outcomes of compound 4 while running in pkCSM online tool.

## molinspiration

originalSMILES CCCCCC1=C(O)C=C2CC(CC\|C=C\|C)OC(=O)C2=C1O  
 miSMILES: CCCCCC1=C(O)C=C2CC(CC\|C=C\|C)OC(=O)C2=C1O  
 7-butyl-6,8-dihydroxy-3-[(E)-pent-3-enyl]-3,4-dihydroisochromen-1-one



<u>Molinspiration bioactivity score</u> v2021.03	
GPCR ligand	0.23
Ion channel modulator	0.07
Kinase inhibitor	-0.25
Nuclear receptor ligand	0.49
Protease inhibitor	-0.02
Enzyme inhibitor	0.45

[Get data as text](#) (for copy / paste).


[Get 3D geometry](#) BETA

This was request 1 out of 1000 available this month for your site 27.147.202.116  
 With technology from Molinspiration you can easily setup similar service also directly on your intranet.  
 Comments or questions ? See our [FAQ](#) and do not hesitate to provide feedback or contact us by email !


[New molecule](#) [Calculate properties](#) [About bioactivity score](#) [MyMolecules](#) [Molinspiration home](#)

©2022 Molinspiration Cheminformatics [Terms of service](#)

Figure S47. Outcomes of compound 4 while running in Molinspiration online tool.



**Figure S48.** Outcomes of compound 5 while running in SwissADME.



**Figure S49.** Outcomes of compound 5 while running in Cell Line Cytotoxicity Predictor (CLC-Pred) online tool.

pkCSM   Predict   Theory   Help   Contact   Acknowledgements   Related Resources   License (non-academic)

## Pharmacokinetic Properties

**Molecule Depiction**

**SMILES**

Property	Model Name	Predicted Value	Unit
Toxicity	AMES toxicity	No	Categorical (Yes/No)
Toxicity	Max. tolerated dose (human)	0.188	Numeric (log mg/kg/day)
Toxicity	hERG I inhibitor	No	Categorical (Yes/No)
Toxicity	hERG II inhibitor	Yes	Categorical (Yes/No)
Toxicity	Oral Rat Acute Toxicity (LD50)	2.257	Numeric (mol/kg)
Toxicity	Oral Rat Chronic Toxicity (LOAEL)	0.801	Numeric (log mg/kg_bw/day)
Toxicity	Hepatotoxicity	Yes	Categorical (Yes/No)
Toxicity	Skin Sensitisation	No	Categorical (Yes/No)
Toxicity	T.Pyrimoris toxicity	0.285	Numeric (log ug/L)
Toxicity	Minnow toxicity	0.287	Numeric (log mM)

**Molecule properties:**

Descriptor	Value
Molecular Weight	783.963
LogP	4.9125
#Rotatable Bonds	9
#Acceptors	9
#Donors	0
Surface Area	335.982

Run another prediction   Back



OPEN SOURCE

Best viewed using Chrome on 1280x1024 resolution and above

**Figure S50.** Outcomes of compound 5 while running in pkCSM online tool.

## References

1. Rahman, M.A.; Uddin, S.B.; Wilcock, C.C. Indigenous knowledge of herbal medicine in Bangladesh-Treatment of jaundice by tribal communities of the Hill tract Districts. *Hamdard Medicus* **2003**, *64*, 25–28.
2. Rahmatullah, M.; Rani, S. Pk.; Imran, M.A.; Jahan, R. The Khasia tribe of Sylhet District, Bangladesh, and their fast-disappearing knowledge of medicinal plants. *J. Altern. Complement. Med.* **2013**, *19*, 599–606.
3. Nath, A.; Maiti, G.G. *Shuktani-* a new ethno-medico recipe among the Sylheti Bengali community of Barak valley, Southern Assam, India. *Indian, J. Tradit. Knowl.* **2012**, *11*, 156–160.
4. Roy, A.; Biswas, S.K.; Chowdhury, A.; Shill, M.C.; Raihan, S.Z.; Muhit, A. Phytochemical screening, cytotoxicity and antibacterial activities of two Bangladeshi medicinal plants. *Pak. J. Biol. Sci.* **2011**, *14*, 905–908.